Cameroon vs Namibia: Average cost of multi drug-resistant tuberculosis treatment
Cameroon
2,825 constant 2022 US$
in 2024
Namibia
3,336 constant 2022 US$
in 2024
Cameroon rank
17th
Namibia rank
14th
Average cost of multi drug-resistant tuberculosis treatment over time
- Cameroon
- Namibia
How they compare
Namibia currently reports 3,336 constant 2022 US$ against 2,825 constant 2022 US$ in Cameroon, a difference of 511 constant 2022 US$.
That makes Namibia's figure about 1.2 times Cameroon's.
Across all 7 years both countries report, Namibia has been ahead every year.
Cameroon ranks 17th and Namibia ranks 14th of 92 countries.
Namibia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Cameroon | Namibia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,084 constant 2022 US$ | 5,099 constant 2022 US$ | 4,016 constant 2022 US$ | Namibia |
| 2020s | 864.4 constant 2022 US$ | 2,966 constant 2022 US$ | 2,102 constant 2022 US$ | Namibia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Cameroon or Namibia?
- Namibia, at 3,336 constant 2022 US$ against 2,825 constant 2022 US$ in Cameroon as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Cameroon and Namibia?
- 511 constant 2022 US$, with Namibia ahead.
- How many years of comparable data are there for Cameroon and Namibia?
- 7 years are reported by both, from 2017 to 2024.
- How do Cameroon and Namibia rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Cameroon ranks 17th and Namibia ranks 14th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.